Alcon Launches Wavelight Plus Personalized LASIK in U.S. and Canada

Alcon Launches Wavelight Plus Personalized LASIK in U.S. and Canada

September 10, 2025

Alcon has officially launched its latest refractive technology, Wavelight Plus, in the United States and Canada. Described as the first fully personalized LASIK treatment, the system aims to bring a new level of precision to laser vision correction by leveraging advanced diagnostics and digital modeling.

Overview of Wavelight Plus Personalized LASIK Technology

Wavelight Plus utilizes ray tracing technology powered by the Sightmap diagnostic device to create a highly detailed three-dimensional “digital eye twin” for each patient. This model is constructed from over 100,000 individual data points, integrating:

       • Ocular wavefront

       • Corneal tomography

       • Biometry measurements

By eliminating reliance on nomogram inputs, the system allows surgeons to perform treatment planning with improved efficiency, predictability, and reproducibility.

“Wavelight Plus marks an exciting new chapter in Alcon’s journey to provide personalized precision in laser eye surgery,” said Sergio Duplan, Alcon Senior Vice President and President, Americas. “For the first time, surgeons in the U.S. and Canada will have the opportunity to deliver a fully tailored refractive treatment that takes into account the unique features of each patient’s eyes.”

Clinical Performance and Real-World Outcomes

Early data from clinical studies and real-world use demonstrate promising visual outcomes with Wavelight Plus:

       • 100% of myopic eyes achieved uncorrected distance visual acuity (UDVA) of 20/20 at 3 months

       • 89% achieved 20/16 UDVA and 50% reached 20/12.5

       • 98% of eyes had UDVA within one line of preoperative corrected distance visual acuity (CDVA)

       • 94% of eyes achieved the same or better CDVA compared to baseline

Global Rollout and Availability

Prior to its debut in North America, Wavelight Plus was introduced in China, as well as several European and Asia-Pacific markets. In Canada, the commercial launch is scheduled for late 2025, with broader availability expected thereafter.

Implementation and Patient Guidance

Alcon encourages interested surgeons to reach out to local representatives for more information on implementation and training opportunities.

Patients considering LASIK with Wavelight Plus are advised to consult with a qualified refractive surgeon to determine their eligibility for the procedure.